Close
Nordic 9Nordic 9

HighLight Capital (investor - Venture Capital)

Japan hlcfund.com
See something wrong or missing? Let us know
Offices:Tokyo
Average round investment:40.78M USD
Average number per year:3.0
Distribution: 2025 (3)
Portfolio companies: Switzerland Allegria TherapeuticsGermany T-curxSwitzerland Nuclidium
Mostly invests in: Switzerland Switzerland (2) Biotech (3)

3 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to HighLight Capital

Name Criteria
United States M12
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
Netherlands BioGeneration Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 3.1
  • Active last 12 months: Yes
United States Pfizer Venture Investments
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 2.9
  • Active last 12 months: Yes
Luxembourg Vesalius Biocapital Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland, Germany
  • Average number of deals per year: 2.5
  • Active last 12 months: Yes
France Relyens Group
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland, Germany
  • Average number of deals per year: 2.5
  • Active last 12 months: Yes
United States Day One Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: Germany
  • Average number of deals per year: 2.4
  • Active last 12 months: Yes
Germany Freigeist Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland, Germany
  • Average number of deals per year: 2.3
  • Active last 12 months: Yes
Belgium Gimv
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland, Germany
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
France Cap Horn
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services
  • Similar business models: B2B
  • Common investees countries: Switzerland, Germany
  • Average number of deals per year: 3.8
  • Active last 12 months: Yes
Luxembourg 3B Future Health Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
Top